Search results
Showing 121 to 135 of 887 results for score
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (HTG318)
Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
Prosthetic intervertebral disc replacement in the cervical spine (HTG217)
Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.
View recommendations for HTG217Show all sections
Sections for HTG217
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
and rates of progression to type 2 diabetes among people with a high risk score but normal blood glucose levels (fasting plasma glucose...
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.
Show all sections
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.
This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.
View quality statements for QS87Show all sections
Sections for QS87
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Assessment at diagnosis
- Quality statement 3: Information and support
- Quality statement 4: Therapeutic exercise
- Quality statement 5: Weight loss
- Quality statement 6: Follow-up
- Quality statement 7: Core treatments before referral for consideration of joint surgery
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.